GALNF Stock Chart & Stats
$106.40
$0.00(0.00%)
At close: 4:00 PM EDT
$106.40
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$98.00 - $139.91
Previous CloseN/A
Volume3.45K
Average Volume (3M)24.00
Market Cap
$5.14B
Enterprise Value$5.30K
Total Cash (Recent Filing)$39.60M
Total Debt (Recent Filing)$1.13B
Price to Earnings (P/E)25.7
Beta<0.01
Next Earnings
Mar 09, 2027EPS Estimate
2.6Next Dividend Ex-DateN/A
Dividend Yield1.47%
Share Statistics
EPS (TTM)3.19
Shares Outstanding50,000,000
10 Day Avg. Volume0
30 Day Avg. Volume24
Financial Highlights & Ratios
PEG Ratio-24.69
Price to Book (P/B)3.29
Price to Sales (P/S)1.18
P/FCF Ratio17.88
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$104.70Price Target Upside-1.60% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)4.73
Revenue Forecast (FY)$5.49B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue And EBIT GrowthBroad-based sales growth and reaffirmed profit guidance indicate durable demand across pharmacies, logistics, products and services. Continued EBIT expansion supports operating resilience and provides visibility into the next several months.
Expanding Healthcare Services EcosystemRising consultation volumes, digital engagement and insured service coverage deepen patient relationships beyond medicine dispensing. This supports recurring healthcare activity, strengthens pharmacy relevance and creates opportunities for future service growth.
Strong Cash Conversion And Resilient ProfitabilityHigh free-cash-flow conversion shows that reported earnings are backed by cash, supporting investment, dividends and debt servicing. Stable operating margins also suggest the distribution and pharmacy model can remain profitable through normal demand variation.
Bears Say
Higher Leverage Reduces Financial FlexibilityThe sharp rise in debt increases sensitivity to earnings disruptions, working-capital swings and financing costs. Leverage above the targeted year-end range could constrain acquisitions, investment capacity and shareholder distributions.
Restructuring And Transition Costs Weigh On EarningsClosing production creates near-term costs, staff support obligations and execution complexity. Although the charge is largely one-off, the transition can distract management and temporarily suppress margins while the business is reorganized.
Regulatory Changes Threaten Pharmacy EconomicsFee and reimbursement changes can reduce revenue or margins in regulated healthcare activities. Longer-term OTC mail-order liberalization may intensify competition and shift customer purchases away from Galenica’s physical pharmacy network.
Galenica AG News
GALNF FAQ
What was Galenica AG’s price range in the past 12 months?
Galenica AG lowest stock price was $98.00 and its highest was $139.91 in the past 12 months.
What is Galenica AG’s market cap?
Galenica AG’s market cap is $5.14B.
When is Galenica AG’s upcoming earnings report date?
Galenica AG’s upcoming earnings report date is Mar 09, 2027 which is in 198 days.
How were Galenica AG’s earnings last quarter?
Galenica AG released its earnings results on Aug 06, 2026. The company reported $2.263 earnings per share for the quarter, missing the consensus estimate of $2.386 by -$0.124.
Is Galenica AG overvalued?
According to Wall Street analysts Galenica AG’s price is currently Overvalued.
Does Galenica AG pay dividends?
Galenica AG pays a Annually dividend of $1.593 which represents an annual dividend yield of 1.47%. See more information on Galenica AG dividends here
What is Galenica AG’s EPS estimate?
Galenica AG’s EPS estimate is 2.6.
How many shares outstanding does Galenica AG have?
Galenica AG has 50,000,000 shares outstanding.
What happened to Galenica AG’s price movement after its last earnings report?
Galenica AG reported an EPS of $2.263 in its last earnings report, missing expectations of $2.386. Following the earnings report the stock price went down -1.612%.
Which hedge fund is a major shareholder of Galenica AG?
Currently, no hedge funds are holding shares in GALNF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galenica AG
Galenica AG stands as a leading healthcare services company, serving both the Swiss market and international clients. Its operations are organized into two principal divisions: "Products & Care" and "Logistics & IT." The "Products & Care" division oversees an extensive network of 520 pharmacies, comprising 368 directly owned outlets and 152 partner-affiliated pharmacies, operating under the recognized brand names of Amavita, Sun Store, and Coop Vitality. Beyond retail pharmacy services, this segment also provides medication for patients receiving home-based treatment. It is also responsible for the introduction and distribution of a diverse portfolio of consumer health, pharmaceutical, and parapharmaceutical products, in addition to offering vital marketing and sales support to its collaborators within the healthcare sector. The "Logistics & IT" division specializes in offering a suite of pre-wholesale services tailored for pharmaceutical and healthcare enterprises. These services encompass essential functions such as secure storage, efficient distribution, and comprehensive debt collection. Furthermore, this segment provides various logistics and information technology solutions, including a master data system specifically developed for the healthcare industry. It actively creates advanced management solutions relevant to the healthcare market and publishes technical information on pharmaceutical products in both printed and electronic formats, alongside delivering complete management tools for pharmacies. Founded in 1927, Galenica AG maintains its headquarters in Bern, Switzerland.
GALNF Stock 12 Month Forecast
Average Price Target
$104.70
▼(-1.60% Downside)
DocMorris
―
DKSH Holding AG
―
Ypsomed Holding AG
―
Sandoz Group Ltd
―
Galderma Group AG
―
Ownership Overview
―
Insiders
6.29% Mutual Funds
― Other Institutional Investors
84.54% Public Companies and
Individual Investors







